When was Impel NeuroPharma founded?

Impel NeuroPharma was founded in 2008.

Where is Impel NeuroPharma located?

Impel NeuroPharma is headquartered in Seattle, United States.

How many employees does Impel NeuroPharma have?

As of Feb 28, 2026, the latest employee count at Impel NeuroPharma is 43.

Is Impel NeuroPharma a funded company?

Impel NeuroPharma is a funded company, having raised a total of $120M across 17 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of Impel NeuroPharma?

Impel NeuroPharma's latest funding was a $***** Conventional Debt round on Mar 12, 2021, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $1.88B in funding in 2026 to date.

What is the annual revenue of Impel NeuroPharma?

Annual revenue of Impel NeuroPharma is $12.7M as on Dec 31, 2022.

Where does Impel NeuroPharma rank among its competitors?

Impel NeuroPharma ranks 4th amongst 87 active competitors, of which 24 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was CraniUS, which secured $19M in Jan, 2026.

Who are the top competitors of Impel NeuroPharma?

Impel NeuroPharma's top competitors include MannKind Corp, OptiNose and Alexza. Among them, CraniUS secured the most recent funding round in January, 2026.

Impel NeuroPharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Impel NeuroPharma is a public company based in Seattle (United States), founded in 2008 by John Hoekman and Rodney Ho. It operates as a Developer of an intranasal drug delivery technology for CNS diseases. Impel NeuroPharma has raised $120M in funding from investors like KKR, 5AM Ventures and VenBio. The company has 87 active competitors, including 24 funded and 16 that have exited. Its top competitors include companies like MannKind Corp, OptiNose and Alexza.

Company Details

Developer of an intranasal drug delivery technology for CNS diseases. It develops non-invasive Precision Olfactory Delivery (POD) nasal devices to develop therapies for Alzheimer's, migraine, and other diseases of the central nervous system. The technology allows a variety of drugs including biologics to be delivered to the brain.

Website: impelnp.com
Social
Phone Number: +1 **********

Key Metrics

Founded Year

2008

Location

Seattle, United States

Stage

Public

Total Funding

$120M in 17 rounds

Latest Funding Round

Conventional Debt, Mar 12, 2021, $*****

Investors

KKR & 8 more

Ranked

4^th among 87 active competitors

Annual Revenue

$12.7M as on Dec 31, 2022

Employee Count

43 as on Feb 28, 2026

Similar Companies

MannKind Corp & 101 more

Exit Details

Public

View Impel NeuroPharma's full profile

Impel NeuroPharma is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
IMPEL PHARMACEUTICALS INC CIN: 1445499 , United States, Active	Jul 23, 2008	$12.7M (As on Dec 31, 2022)	-	-
Impel Neuropharma, Inc CIN: 001-40353 , United States, Active	Sep 04, 2008	-	129 (As on Dec 31, 2021)	-
Impel Pharmaceuticals Inc CIN: 263058238 , United States, Active		-	158 (As on Dec 31, 2022)	-

Impel NeuroPharma got listed on Apr 23, 2021.

Click here to take a look at Impel NeuroPharma's IPO in detail

Impel NeuroPharma has raised a total funding of $120M over 17 rounds. Impel NeuroPharma has 9 institutional investors.

Here is the list of recent funding rounds of Impel NeuroPharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 12, 2021	7302457	Conventional Debt	7731641	7018697	2249910	8825208
Dec 06, 2018	4402707	Series D	6837142	8103704	6775766	Vivo Capital & 2 more
Dec 02, 2016	3050443	Series C	2543380	6063786	4339128	VenBio

Access funding benchmarks and valuations. Sign up today!

View details of Impel NeuroPharma's funding rounds and investors

The founders of Impel NeuroPharma are John Hoekman and Rodney Ho.

Here are the details of Impel NeuroPharma's key team members:

John Hoekman: Co-Founder & CSO of Impel NeuroPharma and founder of 1 other company.
Rodney Ho: Former Co-Founder of Impel NeuroPharma.

View details of Impel NeuroPharma's Founder profiles and Board Members

Impel NeuroPharma's employee count trend

Impel NeuroPharma has 43 employees as of Feb 26. Here is Impel NeuroPharma's employee count trend over the years:

Employee count trend for Impel NeuroPharma

Uncover Impel NeuroPharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Impel NeuroPharma include MannKind Corp, OptiNose and Alexza. Here is the list of Top 10 competitors of Impel NeuroPharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Deerfield & 1 others	72/100
2nd	OptiNose 2000, Morrisville (United States), Acquired	Developer of smart devices for nasal drug delivery	$120M	Avista Capital Partners, Fidelity Investments ... & 6 others	64/100
3rd	Alexza 2000, Mountain View (United States), Public	Developer of products for the treatment of acute and intermittent conditions	$97M	Frazier Healthcare Partners, Versant Ventures ... & 16 others	59/100
4th	Impel NeuroPharma 2008, Seattle (United States), Public	Developer of an intranasal drug delivery technology for CNS diseases	$120M	Vivo Capital, Norwest & 7 others	59/100
5th	Beyond Air 2011, Garden City (United States), Public	Developer of therapeutics for multiple diseases	-	Collage Venture Partners, Cystic Fibrosis Foundation ... Read more	59/100
6th	NeOnc Technologies 2008, Los Angeles (United States), Public	Developer of drug delivery methods for pharma-based therapeutics	$18.7M	NIH, S3 Capital	58/100
7th	CraniUS 2021, Baltimore (United States), Series B	A medical technology company developing drug delivery systems to treat brain diseases and disorders	$39.5M	Mumbai Angels, Lumis Partners & 1 others	58/100
8th	Iconovo 2013, Lund (Sweden), Public	Develops inhalation devices	$3.56M	Smile Incubator, Vinnova & 2 others	55/100
9th	Cordance Medical 2018, Mountain View (United States), Seed	Developer of a non-invasive medical device to open the blood-brain barrier	$8M	Sonder Capital, National Science Foundation ... & 10 others	52/100
10th	Syqe Medical 2011, Tel Aviv (Israel), Late Stage	Developer of a metered-dose inhalation platform for precision plant-based medicine	$83M	Arc Ventures, Wolfpack Ventures & 4 others	45/100